Disease Landscape and Forecast Insights

Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of…

The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…

Three anti-VEGF therapies have long been mainstays of treatment in wet age-related macular degeneration (AMD)—Roche / Genentech’s Lucentis, Regeneron’s Eylea, and Roche / Genentech’s…

Core to Parkinson’s disease (PD) treatment is the co-prescription of various formulations of the gold-standard SOC levodopa with a range of adjunctive therapies from other drug classes (e.g.,…

Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as an effective treatment option against cancer. China…

The multiple sclerosis (MS) therapy market continues to evolve, with each new FDA-approved disease-modifying therapy (DMT) further expanding treatment choices. The newest entrants (e.g., Zeposia,…

Cell therapy uses viable healthy cells to replace, expand, and/or enhance a population of cells in order to achieve a therapeutic effect against a disease. The cell therapy field is rapidly…

The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…

In June 2021, Biogen / Eisai’s anti-Aβ MAb aducanumab (Aduhelm) received accelerated approval from the FDA for the treatment of Alzheimer’s Disease (AD), rendering it the first potential DMT…

Since 2018, seven novel drugs have entered the U.S. market for the acute or preventive treatment of migraine, and at least four more are on the short-term horizon. Understanding how prescribers…

Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses, and the treatment landscape is entrenched with targeted agents. Roche’s Rituxan, Janssen / AbbVie’s…

Disorders such as anxiety, substance use disorder, and insomnia frequently coexist with major depressive disorder (MDD) and present treatment challenges to psychiatrists and primary care…